SecBot SecBot
Biotech Drug Report Generated Oct 30, 2026

BBP-717

BBIO·BridgeBio Pharma, Inc.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Preclinical
Time to market
At least 5-7 years away from potential approval, assuming successful IND filing in 2027, completion of Phase 1-3 trials, and regulatory review. The program has not yet entered human testing.
Why 2/10
No hard dated catalyst is scheduled in the next ~12 months. The IND filing is planned for 2027 without a specific date. BBP-717 is a preclinical program that represents a very small part of BridgeBio's large, diversified pipeline, which includes the approved drug Attruby and the late-stage BBP-418 with a PDUFA on November 27, 2026.
Actionable Insight NEUTRAL

BBP-717 is too early-stage to drive near-term stock movement. The next catalyst to watch is the planned IND filing in 2027, but no specific date has been set. Investors should focus on BridgeBio's nearer-term catalysts: the BBP-418 PDUFA decision on November 27, 2026, and the commercial ramp of Attruby (acoramidis) for ATTR-CM.

Price Chart

Loading chart...

Executive Summary

BBP-717 is a preclinical-stage monoclonal antibody program from BridgeBio Pharma (BBIO, Nasdaq) designed to deplete transthyretin (TTR) amyloid deposits in patients with ATTR cardiomyopathy (ATTR-CM). BridgeBio nominated BBP-717 as a development candidate in Q3 2026, announced on October 29, 2026, and plans to file an Investigational New Drug (IND) application with the FDA in 2027. The program is early-stage and represents a small component of BridgeBio's broader pipeline, which includes the already-approved ATTR-CM stabilizer Attruby (acoramidis) and the BBP-418 program with a PDUFA date of November 27, 2026. BBP-717 faces established competition from Alexion/AstraZeneca's ALXN2220 (cliramitug), which is already in a Phase 3 trial (DepleTTR-CM).

How It Works

BBP-717 is a monoclonal antibody (a type of lab-made protein that mimics the immune system's ability to fight targets) designed to bind to and help clear amyloid deposits -- abnormal clumps of misfolded protein -- that build up in the heart muscle of patients with ATTR cardiomyopathy. Unlike TTR stabilizers (like BridgeBio's approved drug Attruby) that prevent new amyloid from forming, BBP-717 aims to remove existing amyloid deposits, potentially enabling disease reversal.

Trial Status

BBP-717 is in preclinical development. BridgeBio nominated it as a development candidate in Q3 2026 and plans to submit an IND application to the FDA in 2027, with clinical trials projected to begin between 2027 and 2028.

The Two-Sided Case

▲ Bull Case3
BBP-717 targets a large unmet need: there are no approved therapies that actively clear existing TTR amyloid deposits from the heart, only stabilizers that prevent new deposits. If successful, BBP-717 could enable disease reversal in ATTR-CM patients.
BridgeBio has deep expertise in ATTR-CM through its approved drug Attruby (acoramidis), giving it a strong scientific and commercial foundation for a next-generation depleter antibody.
The ATTR-CM market is large and growing: Attruby generated significant Q3 2026 revenue, and a depleter could address patients who already have significant amyloid burden.
▼ Bear Case4
BBP-717 is at the preclinical stage and has not yet entered human trials; most preclinical drug candidates fail to reach the market.
Alexion/AstraZeneca's ALXN2220 (cliramitug/NI006), a similar amyloid-depleter antibody, is already in Phase 3 testing (DepleTTR-CM trial), giving it a multi-year head start over BBP-717.
BBP-717 is a small program within BridgeBio's broad pipeline; the company has many nearer-term priorities including the BBP-418 PDUFA, Attruby commercial expansion, and multiple other clinical programs, so BBP-717 is unlikely to be a near-term value driver.
BridgeBio's stock already has significant exposure to ATTR-CM through Attruby, reducing the marginal impact of an early-stage depleter program.

Upcoming Catalysts

  • IND filing planned for 2027 (no specific date announced)
  • Advancement into clinical trials projected between 2027 and 2028

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BridgeBio Pharma, Inc. PRESS-RELEASE BBIO ·Originating report

Sources · 8

Hover a chip for the title
1 investor.bridgebio.com2 marketbeat.com3 bridgebio.com4 adisinsight.springer.com5 neurimmune.com6 stockanalysis.com7 tradingkey.com8 s205.q4cdn.com